This inventor holds 4 USPTO granted patents. Top assignees: Meiji Seika Kaisha, Ltd., Meji Seika Kaisha Ltd., Waseda University. Active years: 2006-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Obihiro, JP (2011)
- Hokkaido, JP (2006 - 2014)
Company Filing History:


Years Active: 2006-2014
Title: Noboru Inoue: Innovator in Antiprotozoal Compounds and Tick-Borne Infection Solutions
Introduction
Noboru Inoue is a notable inventor based in Hokkaido, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing innovative compounds for treating various diseases. With a total of 4 patents, his work focuses on novel mechanisms of action in antiprotozoal remedies and solutions for tick-borne infections.
Latest Patents
Inoue's latest patents include an antiprotozoal compound derived from coelenterata. This compound aims to develop a remedy with a unique mechanism of action. The patent describes a compound represented by a specific chemical formula, which includes various functional groups that enhance its efficacy. Another significant patent involves a novel galectin, which includes a polynucleotide encoding the same, a vector, and a transformant. This invention has the potential to exterminate ticks and treat or prevent tick-borne infections such as rickettsiosis and viral encephalitis.
Career Highlights
Throughout his career, Noboru Inoue has worked with reputable companies, including Meji Seika Kaisha Ltd. His innovative approach and dedication to research have led to the development of groundbreaking solutions in the pharmaceutical industry.
Collaborations
Inoue has collaborated with notable colleagues, including Kozo Fujisaki and Hideyuki Nagasawa. Their combined expertise has contributed to the advancement of research in their respective fields.
Conclusion
Noboru Inoue's contributions to the field of pharmaceuticals highlight his innovative spirit and commitment to addressing critical health challenges. His patents reflect a deep understanding of complex biological mechanisms and a drive to create effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile